GlassScriptPhysician profile
James A Stoever
NPI 1679515894
$10,829.59
in general payments reported to CMS, 2019-2025
30 companies · $95.95 in 2025
The $95.95 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,682 · 2020: $1,154 · 2021: $365 · 2022: $302 · 2023: $162 · 2024: $68.79 · 2025: $95.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $326.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $3,971.23 | 2019-2020 | |
| Corcept Therapeutics | $3,872.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $493.97 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $384.01 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $374.70 | 2019-2022 | |
| Dexcom, INC. | $291.88 | 2019-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $255.29 | 2019-2025 | Ozempic, Rybelsus |
| Insulet Corporation | $229.64 | 2019-2025 | Omnipod |
| Abbvie INC. | $111.08 | 2019-2020 | |
| Becton, Dickinson and Company | $99.08 | 2019-2022 | |
| Amgen INC. | $88.63 | 2019-2020 | |
| Ibsa Pharma INC. | $84.88 | 2019-2020 | |
| Radius Health, INC. | $78.34 | 2019-2020 | |
| Medtronic Minimed, INC. | $59.18 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $51.56 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $42.87 | 2019 | |
| Amarin Pharma, INC. | $41.67 | 2020-2021 | |
| Beta Bionics, INC. | $39.38 | 2024 | Ilet Bionic Pancreas |
| Medtronic, INC. | $39.08 | 2021-2023 | Inpen Smart Insulin Delivery System |
| Janssen Pharmaceuticals, INC | $31.79 | 2019 | |
| Tandem Diabetes Care, INC. | $29.41 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $28.05 | 2019-2021 | |
| Amryt Pharma Holdings LTD | $22.11 | 2023 | Mycapssa |
| Ipsen Biopharmaceuticals, INC | $20.27 | 2020 | |
| Amneal Pharmaceuticals LLC | $19.03 | 2020 | |
| Shire North American Group INC | $15.57 | 2019 | |
| Lifescan, INC. | $14.49 | 2020 | |
| Alexion Pharmaceuticals, INC. | $14.38 | 2020 | |
| Abbott Laboratories | $13.25 | 2023 | Freestyle Libre |
| Boston Scientific Corporation | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Stoever listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.